Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1806952 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $12.99Day +0.23%Mkt cap $303M1Y −5.4%Off 52W high −71.1%Vol (1Y) 81.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 941 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.2% of sh out |
| Days to cover6.7d |
| 13F net flow (QoQ)+5.79% |
| Top-10 13F concentration76.0% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$31,000 |
| Earnings (TTM)-$246.4M |
| ROE−87.0% |
| Net margin−762355.6% |
| Sales growth 3Y−92.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−57.8% |
| 1Y−5.4% |
| 3Y−77.9% |
| Since incept. (ann.)−46.1% |
Total return through 2026-07-28 · series begins 2022-10-18. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)81.7% |
| Ann. volatility (3Y)100.8% |
| Sharpe (1Y)0.33 |
| Sharpe (3Y)−0.00 |
| Max drawdown (1Y)−69.9% |
| Max drawdown (3Y)−87.3% |
| Beta (3Y vs SPY)1.85 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ARCH Venture Management, LLC | 3.2M | $65M | 13.92% | +17.7% |
| GSK plc | 1.5M | $30M | 6.48% | +0.0% |
| Foresite Capital Management IV, LLC | 800,399 | $16M | 3.43% | +0.0% |
| Orland Properties Ltd | 754,698 | $15M | 3.23% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 718,155 | $14M | 3.08% | new |
| Decheng Capital LLC | 692,050 | $14M | 2.97% | +0.0% |
| Almitas Capital LLC | 577,807 | $12M | 2.48% | +0.0% |
| Foresite Capital Management V, LLC | 477,078 | $10M | 2.04% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$1.10 | — | $2,000 | −71.4% |
| 2025-12-31 | 2026-03-12 | — | — | $6,000 | −45.5% |
| 2025-09-30 | 2025-11-12 | −$2.13 | — | $15,000 | −55.9% |
| 2025-06-30 | 2025-08-12 | −$2.89 | — | $8,000 | −38.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
